A drug discovery company using vast clinical genomics databases to re-define diseases of aging and develop precision medicines in areas of high unmet need.
Character Biosciences has built a platform capable of discovering new drugs and companion diagnostics for complex diseases of aging. They combine years of clinical follow up data, with serial imaging and genomic analysis to reveal groups of patients whose disease progression is driven by a specific molecular pathway. Character uses computational biology to design new precision drugs for those pathways, and a novel application of genetic data to identify the patients who are most likely to benefit from the treatment. This approach has the potential to transform the way complex polygenic diseases of aging are managed, giving hope to a huge number of underserved patients, like those with dry Age-related Macular Degeneration (AMD) - the leading cause of blindness in the elderly in the developed world.